Table 1 Patient characteristics in training set and testing set

Treatment

Paclitaxel

95

47

0.448

Paclitaxel + ABT 888 + Carboplatin

40

17

Paclitaxel + AMG 386

73

23

Paclitaxel + AMG 386 + Trastuzumab

12

4

Paclitaxel + Ganetespib

59

19

Paclitaxel + Ganitumab

69

20

Paclitaxel + MK-2206

32

14

Paclitaxel + MK-2206 + Trastuzumab

25

5

Paclitaxel + Neratinib

70

15

Paclitaxel + Pembrolizumab

44

10

Paclitaxel + Pertuzumab + Trastuzumab

23

10

Paclitaxel + Trastuzumab

16

4

T-DM1 + Pertuzumab

30

9

HR

negative

265

89

1

positive

323

108

HER2

negative

454

157

0.322

positive

144

40

MP

negative

304

102

1

positive

284

95

pCR

negative

398

133

1

positive

190

64

Age (mean, range)

49 (25–77)

50 (23–72)

0.238

Race

American Indian or Alaska Native

4

0

0.434

American Indian or Alaska Native; White

0

1

Asian

43

14

Asian; White

3

1

Black or African American

71

22

Native Hawaiian or Pacific Islander

4

0

Native Hawaiian or Pacific Islander; White

0

1

White

461

157

N/A

2

1

Menopausal status

N/A

103

43

0.362

Perimenopausal

21

7

Postmenopausal

177

64

Premenopausal

287

83

Ethnicity

Hispanic or Latino

76

28

0.723

Not Hispanic or Latino

511

169

N/A

1

0